Patrick Treanor appointed President of Relypsa and member of the Executive Committee of Vifor Pharma Group
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005987/en/
Vifor Pharma Group is pleased to announce the appointment of Patrick Treanor as President of Relypsa on a permanent basis. He is also appointed to the Executive Committee of Vifor Pharma Group with immediate effect. Patrick was appointed interim President of Relypsa, the US affiliate of Vifor Pharma Group on 20 September 2018.
Patrick joined Relypsa in 2015 to establish the sales organisation
for the US launch of Veltassa
. In April 2017,
he was appointed Senior Vice President and Chief Commercial Officer of
Relypsa and has been instrumental in leading the commercialisation
strategy of Veltassa
and driving Relypsa to
achieve its goal of becoming a leader in nephrology and cardio-renal
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit www.viforpharma.com.
Relypsa, Inc., a Vifor Pharma Group company, is a biopharmaceutical company focused on the development and commercialization of late-stage medicines in the iron deficiency, nephrology and cardio-renal therapeutic areas. Relypsa is committed to delivering innovative therapies and improving the lives of patients with serious and life-threatening conditions that are often overlooked and undertreated. The company's first medicine, Veltassa® (patiromer) for oral suspension, was approved by the U.S. FDA in October 2015, making it the first approved medicine for the treatment of hyperkalaemia in more than 50 years. More information is available at www.relypsa.com.
Approximately three million people in the United States with stage 3 or 4 chronic kidney disease (CKD) and/or heart failure have hyperkalaemia, or elevated blood potassium levels. Hyperkalaemia can cause abnormal heart rhythms and even sudden death. There are often no warning signs, meaning a person can unknowingly experience spikes in potassium levels recurrently and be at risk for these cardiac events. Some medicines that are often prescribed to people with CKD and heart failure to help delay progression of their underlying disease and reduce mortality can cause hyperkalaemia as a side effect. These may include renin angiotensin aldosterone system (RAAS) inhibitors such as angiotensin receptor blockers (ARBs), aldosterone antagonists (AAs) and angiotensin-converting-enzyme (ACE) inhibitors.
About Veltassa ®
Veltassa® is a sodium-free potassium binder approved for the treatment of hyperkalaemia. Veltassa® should not be used as an emergency treatment for life-threatening hyperkalaemia because of its delayed onset of action. Made in powder form consisting of smooth, spherical beads, Veltassa® is mixed with water (one-third of a cup) and taken once-a-day. Veltassa® is not absorbed and acts within the gastrointestinal tract. It binds to potassium in exchange for calcium, primarily in the colon. The potassium is then excreted from the body through the normal excretion process.
Important Safety Information
Veltassa® is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa® or any of its components.
Worsening of Gastrointestinal Motility
Use of Veltassa® should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because Veltassa® may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in clinical studies.
Veltassa® binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3 percent of patients treated with Veltassa®. Approximately 9 percent of patients in clinical trials developed hypomagnesemia with a serum magnesium value <1.4 mg/dL. Doctors should monitor serum magnesium and consider magnesium supplementation in patients who develop low serum magnesium levels.
The most common adverse reactions (incidence ≥2 percent) are constipation, hypomagnesemia, diarrhoea, nausea, abdominal discomfort and flatulence. Mild to moderate hypersensitivity reactions were reported in 0.3 percent of patients treated with Veltassa® and included oedema of the lips.
For Veltassa’s® full Prescribing Information, please visit https://www.veltassa.com/pi.pdf.
Media Relations (excl. US)
Head of Corporate Communications
Head of Investor Relations
Media Relations (US)
Director of U.S. Communications Relypsa
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Eurosport Signs an Exclusive Multi-Year Partnership Deal with Outbrain, Which Includes Outbrain’s Smartfeed and Video Technology16.1.2019 14:00 | Tiedote
Outbrain, the world’s leading native advertising platform, announced today it has signed a pan-regional deal with Eurosport, the number one destination for sports fans. The agreement spans 13 markets globally, including the UK, France, Germany, Italy, Spain, Asia, and Australia, and will be powered by Outbrain’s innovative Smartfeed technology. Smartfeed provides a content discovery feed that allows publishers to customise the user experience, improving both engagement and revenue. It is designed for a range of content from promoted articles to editorial pieces to videos, and functions across all devices including desktop, mobile, and apps. Eurosport will also utilise Outbrain’s Amplify platform to promote their own videos. Earlier this year, Outbrain released Focus, a click-to-watch video experience built for engagement and performance, and tailored for high quality and long form video content. Focus consistently results in higher click-through and completion rates, which makes it ide
Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases16.1.2019 14:00 | Tiedote
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with a high unmet need, today announced the expansion of its research collaboration with Cincinnati Children’s Hospital Medical Center to further elucidate the eosinophil-depleting mechanism of action of Knopp’s lead investigational drug, dexpramipexole. Eosinophils are white-blood cells that play a central role in several debilitating conditions, including asthma, hypereosinophilic syndrome (HES), and other inflammatory diseases. Dexpramipexole has been shown to selectively reduce eosinophil levels in multiple clinical trials, including a Phase 2 study in HES and a Phase 2 trial in chronic rhinosinusitis with nasal polyps. Knopp is advancing dexpramipexole into Phase 2 development in severe asthma and Phase 3 development in HES. The research at Cincinnati Children’s Hospital Medical Center is being led by Patricia C. Fu
NexPlayer Supporting Low Latency HLS & DASH Streaming on Android, iOS, Smart TVs, STBs, PCs, and Macs16.1.2019 12:52 | Tiedote
As part of their mission to provide the most advanced feature set, NexPlayer has added low latency functionality to its media players. NexPlayer allows you to enable low latency streaming with HLS and DASH on all devices, solving the latency problem and improving the OTT viewing experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005301/en/ Latency is a serious issue for streaming services, as live playback with HLS and DASH typically falls 30 seconds to a minute behind the live event. With linear TV only 6 seconds behind, OTT viewers find out what happens via social media or text before seeing it firsthand. Now with the support of NexPlayer, media organizations can achieve sub-6 second latency on Android, iOS, Smart TVs, STBs, PCs, and Macs. In the past, the only ways to achieve low latency were through proprietary end-to-end protocols or by foregoing ABR support. Both methods have considerable drawbacks. Propr
Temenos Revolutionises its Banking Software, with the Launch of Two New Cloud-Native, Cloud-Agnostic Products – Temenos Infinity & Temenos T24 Transact to Accelerate Cloud Adoption16.1.2019 11:43 | Tiedote
Temenos (SIX: TEMN) the banking software company, today marked a major milestone with the launch of two new products. Temenos Infinity – a breakthrough digital front office product and Temenos T24 Transact – the next generation in core banking. These new products combine the most complete banking functionality in the market, leveraging 25 years of functionality from 3,000 banks in over 150 countries with the most advanced cloud-native, cloud-agnostic, API first technology and design-led thinking. Through APIs, both products can be implemented independently or integrated. Clients will be able to roll-out new applications in hours utilising advanced continuous deployment tools and methodologies. The conversion from Temenos’ existing Digital Front Office and T24 Core Banking products are automatic and upgrades for existing clients to the new cloud-native, cloud-agnostic Temenos products are available from April 2019. All Temenos SaaS products run on the new Temenos platform. Temenos Infin
Urban Airship Acquires Accengage, Extending Its Worldwide Leadership with Unmatched Presence Across Europe16.1.2019 11:30 | Tiedote
Digital customer engagement company Urban Airship today announced that it has acquired Accengage, continental Europe’s largest provider of mobile CRM and push notifications. Together Urban Airship and Accengage now form the world’s largest mobile customer engagement company, with rapidly growing solutions for apps, websites, SMS, email, mobile wallets and other channels. Customers from each company will quickly benefit from access to new technology and expanded engineering resources, as well as support from Europe’s largest team of digital customer engagement experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005215/en/ Urban Airship customers include 25 percent of the Fortune 100 with companies such as Adidas, ASOS, BBC, Caesars Entertainment, Jet Airways, Shop Direct, Vodafone and Zeit Online. Accengage adds hundreds more global brands including Air France-KLM, Lidl, Mediaset España, OUI.sncf, Orange, Sephora Eu
OpenGate Capital Launches OGx Digital Transformation Capability16.1.2019 11:00 | Tiedote
OpenGate Capital, a global private equity firm, announced today that it has launched OGx, a newly formed digital innovation and business transformation growth capability as part of the firm’s commitment to untap the full potential of its acquired businesses. Developed during 2018, OGx represents the combined power of the firm’s operational excellence best practices with applied exponential technologies and business model innovation to yield the XPotential™ for select investments. Andrew Nikou, OpenGate Capital’s founder and CEO stated, “We are constantly looking for innovative and differentiated ways to accelerate profitable growth in the businesses we acquire. We are excited to launch OGx after successfully piloting it during 2018, recognizing that in this age of increased technology and business disruption, sustainable and scalable value creation within our holding period must go well beyond traditional operating drivers. We believe that a great deal of upside can be created from tak
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme